Adam Raben
Papers
1
Total Citations
3
H-Index
1
About
Adam Raben is a leading clinical researcher in head and neck oncology, with a particular focus on human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). His work centers on optimizing multimodality treatment sequencing to improve patient outcomes. In his highly cited 2024 multi-institutional cohort study, Raben investigated the critical relationship between the timing of surgery and adjuvant radiation therapy (RT) in HPV+ head and neck cancer. His research directly addresses the National Comprehensive Cancer Network (NCCN) recommendation to keep the time from surgery to the start of RT (TSRT) within six weeks, providing real-world evidence on how delays may compromise treatment efficacy. This work has already garnered significant attention, accumulating 3 citations shortly after publication, underscoring its immediate relevance to clinical practice. Raben’s contributions help refine treatment paradigms for HPV+ OPSCC, balancing surgical and radiotherapeutic approaches to maximize survival while minimizing toxicity. His collaborative, multi-institutional approach strengthens the generalizability of his findings, making him a key voice in evidence-based head and neck cancer management.
Research Focus
Key Achievements
Top Papers
- 1